Abstract: Provided is a compound and so on having aldehyde dehydrogenase 2 (ALDH2) activation effect. A compound, a pharmaceutically acceptable salt of the compound, or a prodrug of the compound or the salt, the compound being represented by the following formula (1): wherein A is a heterocycle, R1 and R2 are each independently hydrogen, an alkyl, an alkenyl, or an alkynyl. R3 is an alkyl, ac alkenyl, or as alkynyl, and X1 and X2 are each independently a halogen.

Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: [in the formula (I), A1 represents a methylene group or the like; A2 represents a methylene group or an oxygen atom; A3 represents an azetidinyl group, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, or a homopiperazinyl group which is optionally substituted with —N(R1)R2, —N(R1)R3, and/or —R3; A4 represents —O—, —S—, —S(O)—, —S(O)2—, or —N(R1)—; A5 represents an optionally substituted C3-10 cycloalkylalkyl group or the like; R4 represents a halogen atom or the like; and n represents an integer of 0 or 1].

Abstract: It has been found that a main effect (immunosuppressive activity) of an S1P1 receptor agonist correlates with the selectivity for cells expressing a combination of an S1P1 receptor with G?i2 or G?i3, and that an adverse effect (cardiotoxicity) of an S1P1 receptor agonist correlates with the selectivity for cells expressing a combination of an S1P1 receptor with G?i1.

Abstract: It has been found that a main effect (immunosuppressive activity) of an S1P1 receptor agonist correlates with the selectivity for cells expressing a combination of an S1P1 receptor with G?i2 or G?i3, and that an adverse effect (cardiotoxicity) of an S1P1 receptor agonist correlates with the selectivity for cells expressing a combination of an S1P1 receptor with G?i1.

Abstract: An object of the present invention is to provide a compound having a modulating activity at an S1P receptor which is useful for preventing and treating autoimmune diseases, allergic diseases, and the like. According to the present invention, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof is provided.

Abstract: The present invention relates to a method for maintaining the remission of or treating inflammatory bowel diseases, which comprises administering a maintenance therapeutically effective amount or a therapeutically effective amount of 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzoazepine, a prodrug thereof, or a pharmaceutically acceptable salt thereof to a mammal, wherein the prodrug is 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzoazepine. The method according to the present invention is effective in the maintenance therapy and therapy of the inflammatory bowel diseases and has few side effects. Particularly, the method according to the present invention may exhibit strong maintenance therapeutic and therapeutic effects, even on severe cases having resistance to the conventional therapeutics.

Abstract: An object is to provide an antibody and a vaccine composition which have an ability to practically prevent or treat a Pseudomonas aeruginosa infection, and which can cope with the diversity of clinical isolates derived from patients infected with Pseudomonas aeruginosa. According to the present invention, an antibody against a PA1698 protein that is a type III secretion system component protein of Pseudomonas aeruginosa or against a peptide of the protein, and a vaccine composition comprising the protein or the peptide are provided.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel diseases, which comprises 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzoazepine, a prodrug thereof, preferably 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzoazepine as a prodrug, or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to the present invention is effective in the prophylaxis and therapy of the inflammatory bowel diseases and has few side effects. Particularly, the pharmaceutical composition according to the present invention may exhibit strong prophylactic and therapeutic effects even on severe cases having resistance to the conventional therapeutics.